ValiRx Plc (AIM: VAL) has highlighted its indirect 5.55% shareholding in Ambrose Healthcare following the private pharmaceutical company’s agreement to acquire AM-Pharma for up to €161 million, drawing investor attention
ValiRx Secures Second European Patent for Cytolytix Cancer-Killing Peptide
ValiRx PLC (AIM: VAL) has received notice that the European Patent Office intends to grant a second patent covering the cancer-killing peptide being developed by its majority-owned subsidiary Cytolytix.
ValiRx plc (AIM: VAL) New Evaluation and Material Transfer Agreement
ValiRx plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women’s health and The Royal Institute for the Advancement of Learning/McGill University (“McGill”), a Canadian based
ValiRx Plc (AIM: VAL): Ambrose Extends Option on VAL401
Ambrose Healthcare Exercise Option on VAL 401 Out License Agreement for £16 Million plus Royalties
ValiRx PLC (AIM:VAL) Conclusion of Evaluation Project
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, provides the following update at the conclusion of the Evaluation project from
ValiRx PLC (AIM:VAL) Update on proposed sub-license of VAL201
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health announces that, further to the amendment to the Letter of Intent (“LOI”)
ValiRx PLC (AIM:VAL) Update on proposed sub-license of VAL201
Update on proposed sub-license of VAL201
ValiRx PLC (AIM:VAL) Business Update
ValiRx plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women’s health, is today pleased to provide an operational update.
ValiRx PLC (AIM:VAL) Agreement to License VAL401 to Ambrose Healthcare
ValiRx Plc (AIM: VAL), a life science company focusing on cancer therapeutics and women’s health, announces that ValiSeek Limited (“ValiSeek”), has entered into an exclusive Option Agreement to license VAL401
ValiRx PLC – Expanded agreement with University of Barcelona
ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today pleased to announce that the evaluation agreement announced on 14 February 2022
ValiRx PLC (AIM:VAL) Operational Update
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce today the signature of a lease for
ValiRx PLC (AIM:VAL) Launch of Broker Offer to raise a maximum of £500,000
Launch of Broker Offer to raise a maximum of £500,000